Current medications are associated with unsatisfying clinical responses in SLE-associated DAH patients, including azathioprine, cyclophosphamide, cyclosporine, intravenous Igs, mycophenolate mofetil and pulse methylprednisolone in addition to the routine prescription of high-dose corticosteroids [1,3,16]. The gene discussed is CUBN; the disease is systemic lupus erythematosus.